DOP2014000238A - Procedimiento para la fabricación de medicamentos útiles para el tratamiento de las dermatosis sensibles a los esteroides - Google Patents

Procedimiento para la fabricación de medicamentos útiles para el tratamiento de las dermatosis sensibles a los esteroides

Info

Publication number
DOP2014000238A
DOP2014000238A DO2014000238A DO2014000238A DOP2014000238A DO P2014000238 A DOP2014000238 A DO P2014000238A DO 2014000238 A DO2014000238 A DO 2014000238A DO 2014000238 A DO2014000238 A DO 2014000238A DO P2014000238 A DOP2014000238 A DO P2014000238A
Authority
DO
Dominican Republic
Prior art keywords
manufacture
chloro
methyl
sterible
procedure
Prior art date
Application number
DO2014000238A
Other languages
English (en)
Inventor
Pankaj Agarwal
Vinod Kumar
Qing Xie
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48143295&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2014000238(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of DOP2014000238A publication Critical patent/DOP2014000238A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a un procedimiento para la fabricación de medicamentos útiles para tratar las dermatosis sensibles a los esteroides en un mamífero, incluyendo un ser humano, que lo necesite, contentivos de una cantidad terapéuticamente eficaz de un compuesto seleccionado del grupo que consiste en: N-{(1S)-2-amino-1-[(3-fluorofenil)metil]etil}-5-cloro-4-(4-cloro-1-metil-1H-pirazol-5-il)-2-tiofenocarboxamida o una de sus sales farmacéuticamente aceptables, y el compuesto N-{(1S)-2-amino-1-[(3,4-difluorofenil)metil]etil}-5-cloro-4-(4-cloro-1-metil-1H-pirazol-5-il)-2-furanocarboxamida o una de sus sales farmacéuticamente aceptables.
DO2014000238A 2012-04-24 2014-10-23 Procedimiento para la fabricación de medicamentos útiles para el tratamiento de las dermatosis sensibles a los esteroides DOP2014000238A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261637390P 2012-04-24 2012-04-24
US201361782565P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
DOP2014000238A true DOP2014000238A (es) 2014-12-15

Family

ID=48143295

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2014000238A DOP2014000238A (es) 2012-04-24 2014-10-23 Procedimiento para la fabricación de medicamentos útiles para el tratamiento de las dermatosis sensibles a los esteroides

Country Status (26)

Country Link
US (2) US20150087683A1 (es)
EP (1) EP2841053A1 (es)
JP (1) JP2015514792A (es)
KR (1) KR20150010943A (es)
CN (1) CN104302275A (es)
AR (1) AR090795A1 (es)
AU (1) AU2013254849B2 (es)
BR (1) BR112014026706A2 (es)
CA (1) CA2873751A1 (es)
CL (1) CL2014002861A1 (es)
CO (1) CO7111283A2 (es)
CR (1) CR20140491A (es)
DO (1) DOP2014000238A (es)
EA (1) EA201491914A1 (es)
HK (1) HK1201726A1 (es)
IL (1) IL235159A0 (es)
MX (1) MX2014012904A (es)
NZ (1) NZ628394A (es)
PE (1) PE20142356A1 (es)
PH (1) PH12014502400A1 (es)
SG (1) SG11201406409VA (es)
TW (1) TW201347758A (es)
UA (1) UA113875C2 (es)
UY (1) UY34762A (es)
WO (1) WO2013160222A1 (es)
ZA (1) ZA201407345B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111821299A (zh) * 2019-04-16 2020-10-27 天津合美医药科技有限公司 噻吩衍生物用于治疗免疫球蛋白E（IgE）介导的疾病的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006002734A1 (en) * 2004-07-01 2006-01-12 Unilever N.V. Moisture barrier
CA2578384A1 (en) * 2004-09-06 2006-03-16 Altana Pharma Ag Novel pyrazolopyrimidines
US7705014B2 (en) * 2005-04-12 2010-04-27 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
SG172926A1 (en) * 2009-01-30 2011-08-29 Glaxosmithkline Llc Crystalline n-{(1-s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
CA2777085A1 (en) * 2009-10-08 2011-04-14 Glaxosmithkline Llc Combination
WO2011146710A1 (en) * 2010-05-21 2011-11-24 Glaxosmithkline Llc Combination

Also Published As

Publication number Publication date
US20150087683A1 (en) 2015-03-26
BR112014026706A2 (pt) 2017-06-27
HK1201726A1 (en) 2015-09-11
IL235159A0 (en) 2014-12-31
CA2873751A1 (en) 2013-10-31
KR20150010943A (ko) 2015-01-29
AR090795A1 (es) 2014-12-10
WO2013160222A1 (en) 2013-10-31
AU2013254849A1 (en) 2014-11-06
EA201491914A1 (ru) 2015-01-30
PE20142356A1 (es) 2015-01-30
EP2841053A1 (en) 2015-03-04
JP2015514792A (ja) 2015-05-21
MX2014012904A (es) 2014-11-21
NZ628394A (en) 2016-02-26
UA113875C2 (uk) 2017-03-27
CO7111283A2 (es) 2014-11-10
PH12014502400A1 (en) 2015-01-12
CN104302275A (zh) 2015-01-21
UY34762A (es) 2013-11-29
TW201347758A (zh) 2013-12-01
ZA201407345B (en) 2015-11-25
CR20140491A (es) 2014-12-22
AU2013254849B2 (en) 2016-05-26
CL2014002861A1 (es) 2015-01-16
SG11201406409VA (en) 2014-11-27
US20160143885A1 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
CY1119200T1 (el) Νεα παραγωγα βενζιμιδαζολιου ως ερ4 ανταγωνιστες
CO2018005640A2 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
AR085219A1 (es) 6-cicloalquil-pirazolopirimidinonas para el tratamiento de trastornos del snc
UY34974A (es) Piridazina 1,4 disustituida, análogos de la misma y métodos para tratar las enfermedades relacionadas con deficiencia del smn
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
UY34917A (es) Inhibidores de la producción de leucotrieno-a4-hidrolasa (lta4h), composiciones farmacéuticas que los contienen y proceso para su preparación
JP2016526024A5 (es)
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
EA201490888A1 (ru) Новые производные пурина и их применение для лечения заболевания
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
EA201491933A1 (ru) Дигидрат соединения бензотиофена или его соли и способ его получения
UY35142A (es) Derivados de triazolopirazinas como inhibidores de brd4
AR093247A1 (es) Agente profilactico y/o terapeutico para sintomas conductuales y psicologicos asociados con la enfermedad neurodegenerativa o sintomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo
UY35827A (es) Derivados de triazolopirazina como inhibidores de la proteína brd4
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
CL2014001838A1 (es) Compuestos derivados de fluormetil-5,6-dihidro-4h-[1,3]oxazin-2-ilamina, como inhibidores de la bace1; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de alzheimer, esclerosis lateral amiotrofica, cancer, enfermedades cardiovasculares y enfermedades gastrointestinales, entre otras.
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
CO2017007325A2 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
CU20160140A7 (es) CROMENE Y 1,1 A,2,7B- tetrahidrociclopropa[C]CROMENE PIRIDOPIRAZINEDIONES COMO MODULADORES DE GAMMA-SECRETASA
EA201490653A1 (ru) Производные эстра-1,3,5(10),16-тетраен-3-карбоксамида, способ их получения, содержащие их фармацевтические препараты, а также их применение для получения лекарственных средств
EA201391027A1 (ru) Комбинация
UY36228A (es) Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen
EA201691299A1 (ru) Применение лахинимода для замедления прогрессирования болезни хантингтона